Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Low-Dose Anti-Thymocyte Globulin for Graft-Versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplant

Adam Bryant, MD, Ranjeeta Mallick, Lothar B. Huebsch, MD, David S. Allan, MD FRCPC, Harold Atkins, MDFRCPC, Grizel Anstee, MD, Isabelle Bence-Bruckler, MD FRCPC, Linda Hamelin, Michael Hodgins, MD, Mitchell Sabloff, MDM, Nicholas Scrivens, Dawn C. Maze, MDFRCPC,MSc, Christopher N. Bredeson, MD MSc, FRCPC, Natasha Kekre, MDMPH, FRCPC

Blood (2016) 128 (22): 5782.

https://doi.org/10.1182/blood.V128.22.5782.5782

Published: 2016

Journal Articles

Bendamustine and Rituximab Versus Conventional Chemoimmunotherapy As a Frontline Treatment for Patients with Indolent B-Cell Lymphoma: A Cost-Effectiveness Analysis

Andrew Aw, MD MEng, FRCPC, Kathryn Coyle, BScPharm, MSc, Isabelle Bence-Bruckler, MD FRCPC, Christopher N. Bredeson, MD MSc, FRCPC, Doug Coyle, MA, MSc, PhD

Blood (2016) 128 (22): 1186.

https://doi.org/10.1182/blood.V128.22.1186.1186

Published: 2016

Journal Articles

Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Dennis Dong Hwan Kim, MD PhD, Isabelle Bence-Bruckler, MD FRCPC, Donna L. Forrest, MD, Mary Lynn Savoie, MD, Stephen Couban, MD, Lambert Busque, MD PhD FRCPC, Robert Delage, MD MSc, FRCP, Pierre Laneuville, MD FRCPC, Elena Liew, MD, Anargyros Xenocostas, MD, Kristjan Paulson, MD FRCPC, Suzanne Kamel-Reid, PhD DABMG, FACMG, Jeff H. Lipton, MD PhD, Brian Leber, MD

Blood (2016) 128 (22): 1922.

https://doi.org/10.1182/blood.V128.22.1922.1922

Published: 2016

Journal Articles

Failure to Achieve Early Molecular Milestone within 3 Months Is Associated with Higher Risk of Relapse and Worse Survival after Allogeneic Hematopoietic Stem Cell Transplant for Chronic Myeloid Leukemia Patients, Especially after Tyrosine Kinase Inhibitor Failure

Dennis Dong Hwan Kim, MD PhD, Mary Lynn Savoie, MD, Isabelle Bence-Bruckler, MD FRCPC, Lothar B. Huebsch, MD, Marc Lalancette, MDFRCP-C, Christopher M. Hillis, MD FRCPC, Irwin Walker, MBBS, Donna L. Forrest, MD, Jeff H. Lipton, MD PhD

Blood (2016) 128 (22): 1907.

https://doi.org/10.1182/blood.V128.22.1907.1907

Published: 2016

Journal Articles

Ibrutinib Vs Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL)

Blood (2015) 126 (23): 469.

https://doi.org/10.1182/blood.V126.23.469.469

Published: 2015

Journal Articles

Lymphoma Symptoms: Data from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL) Treated with Ibrutinib Vs. Temsirolimus

Georg Hess, MD, Simon Rule, MD, Wojciech Jurczak, Mats Jerkeman, MD PhD, Rodrigo Santucci, MD, Chiara Rusconi, MD, Dolores Caballero, Cristina M. Joao, MD PhD, Mathias Witzens-Harig, MD, Isabelle Bence-Bruckler, MD FRCPC, Seok-Goo Cho, Nibedita Bandyopadhyay, PhD, Jenna Goldberg, MD, John Bothos, PhD, Christopher Enny, BS, Jessica Vermeulen, MD PhD, Shana Traina, PhD, Martin H. Dreyling, MD PhD

Blood (2015) 126 (23): 1542.

https://doi.org/10.1182/blood.V126.23.1542.1542

Published: 2015

Journal Articles

Combined Modality Therapy in the Upfront Treatment of Patients with Primary Central Nervous System Lymphoma: A Systematic Review

Andrew Aw, MD FRCPC, Lee Mozessohn, MD FRCPC, Isabelle Bence-Bruckler, MD FRCPC, Rena Buckstein, MD FRCPC, Matthew Cheung, MD SM, FRCPC

Blood (2015) 126 (23): 5606.

https://doi.org/10.1182/blood.V126.23.5606.5606

Published: 2015

Journal Articles

Retrospective Analysis of Allogeneic Transplant Outcomes in Chronic Myeloid Leukemia Patients with Tyrosine Kinase Inhibitors Failure

Dennis Dong Hwan Kim, MDPhD, Isabelle Bence-Bruckler, MD FRCPC, Christopher M. Hillis, MD FRCPC, Irwin Walker, MBBS, Suzanne Kamel-Reid, PhD, Jeffrey H. Lipton, MD PhD

Blood (2014) 124 (21): 4554.

https://doi.org/10.1182/blood.V124.21.4554.4554

Published: 2014

Journal Articles

Safety of PK-Guided IV Bu Cy VP-16 Preparative Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Lymphoma: Findings From a Multi-Center Phase II Study in North America

Blood (2012) 120 (21): 813.

https://doi.org/10.1182/blood.V120.21.813.813

Published: 2012

Journal Articles

A Canadian Expanded Access Trial of Oral Nilotinb in Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

Robert Delage, MD, MSc, FRCP, A. Robert Turner, MD, FRCPC, Brian Leber, MD, Wanda S. Hasegawa, MD, Denis-Claude Roy, MD, Mary Lynn Savoie, MD, Heather A Leitch, MD, PhD, Isabelle Bence-Bruckler, MD, FRCPC, Donna L. Forrest, MD, Sindu Kanjeekal, MD, Sehdev Sandeep, MD, Pierre Laneuville, MD, Sarit Assouline, MD, Kuljit Grewal, MD, Michael J. Kovacs, MD, FRCPC, Wendy Lam, MD, Annie Woo, M.Sc., Pierre Beauparlant, Ph.D., Jeffrey H. Lipton, MD, PhD

Blood (2011) 118 (21): 4437.

https://doi.org/10.1182/blood.V118.21.4437.4437

Published: 2011

Journal Articles

Interim Restaging PET/CT-Guided High Dose Sequential Induction Therapy with Autologous Stem Cell Transplantation (ASCT) Does Not Improve Outcome for Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL). ClinicalTrials.Gov Identifier: NCT00530179

Douglas A. Stewart, MD, FRCPC, Reinhard Kloiber, MD, FRCPC, Nizar Bahlis, MD, Peter Duggan, MD, FRCPC, Andrew Daly, MD, FRCPC, Christian Fibich, MD, David Blair Macdonald, MD, FRCPC, Isabelle Bence-Bruckler, MD, FRCPC

Blood (2011) 118 (21): 500.

https://doi.org/10.1182/blood.V118.21.500.500

Published: 2011

Journal Articles

A Phase 2, Double-Blind, Placebo-Controlled Trial of Rituximab + Galiximab Vs Rituximab + Placebo In Advanced Follicular Non-Hodgkin's Lymphoma (NHL)

Isabelle Bence-Bruckler, MD, FRCPC, David Macdonald, MD, FRCPC, Patrick J Stiff, MD, Byron McKinney, MS, Katherine L. Ruffner, MD, Lynn Wilson, Margaret Whiteley, BSc, Brad Kahl, MD

Blood (2010) 116 (21): 428.

https://doi.org/10.1182/blood.V116.21.428.428

Published: 2010

Journal Articles

Assessment of Minimal Residual Disease (MRD) In Relapsed CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab (REACH)

Blood (2010) 116 (21): 1390.

https://doi.org/10.1182/blood.V116.21.1390.1390

Published: 2010

Journal Articles

FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone.

David Dornan, Ph.D, Olivia Spleiss, Ph.D, Ru-Fang T Yeh, PhD, Guillemette Duchateau-Nguyen, PhD, Tadeusz Robak, Sergey I Moiseev, MD, Anna Dmoszynska, MD, Philippe Solal-Celigny, MD, Krzysztof Warzocha, MD, PhD, Javier Loscertales, MD, John Catalano, MD, Boris V Afanasiev, MD, Loree Larratt, MD, Viktor A Rossiev, MD, PhD, Isabelle Bence-Bruckler, MD, FRCPC, Christian H. Geisler, MD, DMSc, Marco Montillo, MD, Michael K. Wenger, MD, Martin Weisser, MD

Blood (2009) 114 (22): 2338.

https://doi.org/10.1182/blood.V114.22.2338.2338

Published: 2009

Journal Articles

Interim Restaging FDG-PET/CT to Guide Use of High Dose Sequential Induction Therapy with Rituximab-Dose-Intensive Cyclophosphamide, Etoposide, Cisplatin (RDICEP) and Rituximab-Carmustine, Etoposide, Cytarabine, Melphalan (RBEAM) and Autologous Stem Cell Transplantation (ASCT) for Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL). ClinicalTrials. Gov Identifier: NCT00530179.

Douglas A. Stewart, MD, FRCPC, Peter Duggan, MD, FRCPC, Nizar J Bahlis, MD, Andrew Daly, MD, FRCPC, Michelle Geddes, MD, FRCPC, Reinhard Kloiber, MD, FRCPC, Christian Fibich, MD, David Blair Macdonald, MD, FRCPC, Isabelle Bence-Bruckler, MD, FRCPC

Blood (2009) 114 (22): 3414.

https://doi.org/10.1182/blood.V114.22.3414.3414

Published: 2009

NARROW

Low-Dose Anti-Thymocyte Globulin for Graft-Versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplant

Bendamustine and Rituximab Versus Conventional Chemoimmunotherapy As a Frontline Treatment for Patients with Indolent B-Cell Lymphoma: A Cost-Effectiveness Analysis

Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Failure to Achieve Early Molecular Milestone within 3 Months Is Associated with Higher Risk of Relapse and Worse Survival after Allogeneic Hematopoietic Stem Cell Transplant for Chronic Myeloid Leukemia Patients, Especially after Tyrosine Kinase Inhibitor Failure

Ibrutinib Vs Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL)

Lymphoma Symptoms: Data from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL) Treated with Ibrutinib Vs. Temsirolimus

Combined Modality Therapy in the Upfront Treatment of Patients with Primary Central Nervous System Lymphoma: A Systematic Review

Retrospective Analysis of Allogeneic Transplant Outcomes in Chronic Myeloid Leukemia Patients with Tyrosine Kinase Inhibitors Failure

Safety of PK-Guided IV Bu Cy VP-16 Preparative Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Lymphoma: Findings From a Multi-Center Phase II Study in North America

A Canadian Expanded Access Trial of Oral Nilotinb in Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

Interim Restaging PET/CT-Guided High Dose Sequential Induction Therapy with Autologous Stem Cell Transplantation (ASCT) Does Not Improve Outcome for Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL). ClinicalTrials.Gov Identifier: NCT00530179

A Phase 2, Double-Blind, Placebo-Controlled Trial of Rituximab + Galiximab Vs Rituximab + Placebo In Advanced Follicular Non-Hodgkin's Lymphoma (NHL)

Assessment of Minimal Residual Disease (MRD) In Relapsed CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab (REACH)

FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only